General discussion, page-163

IMO, you can forget about them saying anything about the inhalers as a potential treatment for COVID. If they were a good treatment, they would have already said so. They came up with the ARDS trial to compensate for the inhalers not being the ultimate treatment. Furthermore, I wouldn't be surprised if the trials are pushed back into the late third quarter. The biotech industry is renowned for having delays. I'll be interested to see how much cash they've spent this quarter out of the $5M - Possibly $2M. But that's a gut feeling.